Answer

IFF Scent recovery: drivers, 2H evolution for Fine Fragrance vs Consumer Fragrance, and the R&D plan supporting 2027

1) Drivers of Scent’s recovery (what management points to)

Management describes Scent’s recovery as a combination of (a) rebuilding R&D capability and product pipeline, (b) regaining/defending share via better go-to-market and customer execution, and (c) navigating mix/volatility effects (notably Middle East impacts in Fine Fragrance) while preparing for normalization into later quarters. ¹²³

A. R&D capability and pipeline are back on track

Management says the R&D pipeline “2.5 years ago was not what it should have been,” and that since then IFF has built a “very strong R&D capability,” including “great perfumers” and a “great pipeline of molecules as well as delivery systems.” ¹
This is framed as not just activity but capability—i.e., strengthening “strengths and addressing gaps,” with optimism about the future of Scent. ¹

B. Commercial execution and market share rebuilding

In the question prompt, management is directly asked about “invest in R&D, grow your market share back,” implying that recovery is tied to both innovation and share gains; management’s response emphasizes rebuilding R&D and the go-to-market approach with customers. ⁴²
Specifically, management attributes Consumer Fragrance improvement to rebuilding “the R&D capability [and] go-to-market approach with customers” while “trying to drive market share gains.” ²

C. Fine Fragrance volatility management (Middle East) + recovery timing

Fine Fragrance faced uncertainty/volatility tied to the Middle East, and management states the Q2 result was “up slightly positive” versus an expectation of “down in Fine Fragrance mid-single digits” entering the quarter. ³
Management also indicates they are “factoring in a softer Q3” and then “start to see some recovery” moving into Q4. ³²

D. Fragrance Ingredients growth is a key near-term engine (and is expected to normalize)

While your question is about Scent and the evolution of Fine Fragrance vs Consumer Fragrance, IFF also links overall Scent recovery to Fragrance Ingredients performance:

Scent delivered 8% sales growth in Q2, with performance driven by “double-digit growth in Fragrance Ingredients” and “high single-digit increase in Consumer Fragrance.” ⁵
Fragrance Ingredients grew “north of 20%” in Q2, with management explicitly saying part of that was a challenging year-ago comp (“comparing to a down 10% or more in the year ago period”) and part was using synthetics opportunistically amid macro/supply disruptions and higher Brent crude prices. ³
They expect normalization going forward, with growth shifting “towards the higher value-added ingredients versus the traditional synthetics.” ³
Management further notes Fragrance Ingredients is “very strong in Q2” and expects it to “normalize on a go-forward basis,” with year-over-year performance “slightly under pressure” (i.e., it’s a headwind vs Q2 levels). ²

Bottom line on drivers: management’s recovery story blends (1) capability and innovation rebuild (R&D pipeline/perfumers/molecules/delivery systems), (2) commercial execution and market-share efforts, and (3) managing volatility/mix effects in Fine Fragrance, while acknowledging near-term Fragrance Ingredients strength will fade as it normalizes. ¹²³

2) How Fine Fragrance and Consumer Fragrance should evolve in 2H (Q3–Q4 trajectory)

A. Fine Fragrance: softer Q3, stronger Q4; 2H mid-single-digit growth

Management provides an explicit directional split:

Fine Fragrance is expected to be “a little bit softer in Q3, but a stronger Q4.” ²
On a second-half basis, management targets “mid-single-digit range” growth for Fine Fragrance. ²
This is also consistent with management having expected Fine Fragrance to be down mid-single digits into Q2 (but ending slightly positive), and then expecting a “softer Q3” due to volatility plus a “big comp” (Q3 last year grew 20%), followed by recovery in Q4. ³

B. Consumer Fragrance: low single-digit in 2H, normalization from a strong Q2

Management’s expectations for Consumer Fragrance are similarly directional:

Consumer Fragrance is expected to be in the “low single-digit range” for the go-forward basis after a strong Q2. ²
Management notes Q2 was “a really good Q2 at a high single-digit number,” but that it will “normalize… to kind of a low single-digit number” go-forward. ²
In the Q2 segment commentary, Scent’s performance included “high single-digit increase in Consumer Fragrance,” which aligns with the idea that Q2 was the stronger point before normalization. ⁵

C. How Middle East noise fits into the 2H framework

Management explicitly links the Fine Fragrance recovery timing to Middle East-related uncertainty: they “managed the challenges in the Middle East,” yet still plan for a “softer Q3” and recovery beginning in Q4. ³
They also emphasize comparables: Q3 last year Fine Fragrance grew “20%,” making the upcoming comp difficult even if underlying demand is improving. ³

Summary of 2H evolution (as guided):

Fine Fragrance: softer Q3, stronger Q4; 2H mid-single-digit growth. ²³
Consumer Fragrance: normalization from high single digits in Q2 to low single-digit go-forward growth. ²
Contextual cross-effect: Fragrance Ingredients is expected to normalize (slight YoY pressure), which could influence consolidated Scent dynamics even as Fine/Consumer segments follow their guided ranges. ²³

3) Plan for R&D to support 2027 (what management says they’re building and why it matters)

A. What they’ve achieved so far (foundation already rebuilt)

Management describes concrete R&D strengthening outcomes:

They state they now have “a very strong R&D capability” and “a great pipeline of molecules as well as delivery systems.” ¹
They highlight the presence of “great perfumers” developing “leading-edge new Fine Fragrances and Consumer Fragrances.” ¹
They characterize the work as both strengthening “strengths” and “addressing… gaps,” and say they are “optimistic about the future of Scent.” ¹

B. Why R&D is strategically linked to performance into/through 2027

Even though IFF’s transcript excerpt doesn’t provide a month-by-month 2027 roadmap, management explicitly frames the R&D work as part of regaining competitive position and enabling longer-term evolution:

Management says the Fragrance Ingredients repositioning to “higher-value natural products” is “underway,” taking “a little bit more time,” and that “as we go into next year and the year after, we believe we’ll have a really strong competitive position.” ²
In parallel, management ties Consumer Fragrance improvement to rebuilding “the R&D capability [and] go-to-market approach with customers” to drive “market share gains.” ²
And they describe a broader Remainco innovation reinforcement: they emphasize “innovation matters” and that IFF must “critically continue to reinvest” in R&D to sustain a “circle” where investments lead to better growth and margin, enabling further reinvestment. ⁶

C. R&D support structure: capability, perfumers, pipeline, and delivery systems

The strongest “plan” signals in the excerpt are about the components of the innovation engine that are intended to carry through the later horizon:

Capability: “very strong R&D capability.” ¹
People: “great perfumers.” ¹
Output/pipeline: “pipeline of molecules” and “delivery systems.” ¹
Target categories: “leading-edge new Fine Fragrances and Consumer Fragrances.” ¹

Taken together, this is the management’s stated mechanism for sustaining evolution beyond the near-term and supporting 2027 competitiveness: improve the product creation engine so that market-share and competitive position gains can materialize as normalization/comparables stabilize. ¹²⁶

Conclusion (directly answering the question)

Drivers of Scent’s recovery: management attributes the recovery to rebuilding R&D capability and pipeline (molecules + delivery systems), strong perfumer-led innovation for Fine/Consumer Fragrances, and improved go-to-market execution aimed at regaining market share, while Fine Fragrance recovery timing is shaped by Middle East volatility and tough comps. ¹²³
2H evolution: Fine Fragrance should be softer in Q3 and stronger in Q4, translating to mid-single-digit growth in 2H; Consumer Fragrance should normalize from a strong Q2 to low single-digit growth in the go-forward period. ²³
R&D plan to support 2027: management describes a strengthened R&D “capability + perfumers + pipeline of molecules and delivery systems” platform that is already producing leading-edge Fine and Consumer fragrances, and frames continued reinvestment in innovation as essential to achieving durable growth and enabling sustained competitiveness into later years (including the “next year and the year after” window). ¹²⁶

References

International Flavors & Fragrances Inc. (IFF) earnings transcript 2026 - Q2

Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.

IFF Scent Recovery Gains Momentum in Q2 2026 with Second-Half Outlook

Sources used

Research question

Answer

IFF Scent recovery: drivers, 2H evolution for Fine Fragrance vs Consumer Fragrance, and the R&D plan supporting 2027

1) Drivers of Scent’s recovery (what management points to)

A. R&D capability and pipeline are back on track

B. Commercial execution and market share rebuilding

C. Fine Fragrance volatility management (Middle East) + recovery timing

D. Fragrance Ingredients growth is a key near-term engine (and is expected to normalize)

2) How Fine Fragrance and Consumer Fragrance should evolve in 2H (Q3–Q4 trajectory)

A. Fine Fragrance: softer Q3, stronger Q4; 2H mid-single-digit growth

B. Consumer Fragrance: low single-digit in 2H, normalization from a strong Q2

C. How Middle East noise fits into the 2H framework

3) Plan for R&D to support 2027 (what management says they’re building and why it matters)

A. What they’ve achieved so far (foundation already rebuilt)

B. Why R&D is strategically linked to performance into/through 2027

C. R&D support structure: capability, perfumers, pipeline, and delivery systems

Conclusion (directly answering the question)

References

Keep Reading

IFF's Scent Recovery Gains Traction as Fine and Consumer Fragrance Evolve in 2H 2026

Keep Reading

Keep Reading

IFF's Scent Recovery Gains Traction as Fine and Consumer Fragrance Evolve in 2H 2026

IFF's Scent Recovery Fueled by 2026 Q2 R&D Reboot; H2 Outlook and 2027 Plan

IFF’s Scent Recovery Driven by Fragrance Ingredients, R&D Push Toward 2027 in Q2 2026

IFF Scent Recovery Driven by Fragrance Ingredients, 2H 2026 Outlook, and 2027 R&D Plan

IFF Scent Recovery Gains Momentum in Q2 2026, H2 Outlook and 2027 R&D Plan

IFF Scent Recovery Fueled by Fragrance Ingredients, Q2 2026 Outlook, and 2027 R&D Plan

IFF Scent Recovery Strengthens as Q2 2026 Highlights R&D Path to 2027

IFF Scent Recovery Gains Traction in Q2 2026, R&D Plan Sets 2027 Outlook

IFF Scent Recovery Gains Momentum in 2H, R&D Plan Targets 2027

IFF Scent Recovery Driven by Fragrance Ingredients; H2 Outlook and 2027 R&D Plan

IFF's Scent Recovery Fueled by Fragrance Ingredients Momentum and 2027 R&D Plan

IFF Q2 2026 Highlights on Scent Recovery, H2 Fragrance Outlook, and 2027 R&D Plan